Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparative metabolomic and transcriptomic analysis revealing the role of salicylic acid for short-term response with arginine and myristic acid for long-term tolerance under salt stress in watermelon (<i>Citrullus lanatus</i> L.).

Frontiers in plant science·2026

Same author

Correction: Subcellular and macrostructural immediate responders to airblast traumatic brain injury.

Scientific reports·2026

Same author

Myeloid Cell Targeting Strategies Show Limited Durable Activity in the Breast Cancer Tumor Microenvironment and Do Not Enhance the Activity of Thermally Ablative Focused Ultrasound.

Cells·2026

Same author

Curcumin reduces the pathogenicity of Streptococcus suis serotype 2 in mice by targeting suilysin.

Pakistan journal of pharmaceutical sciences·2026

Same author

Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer.

Nature immunology·2026

Same author

Interpretable ensemble meta-learning for estimated ultimate recovery prediction in shale gas wells.

Scientific reports·2026

Search research articles

Related Experiment Video

Updated: May 3, 2026

Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro

Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro

Published on: March 7, 2022

Metabolic influences that regulate dendritic cell function in tumors.

Han Dong¹, Timothy N J Bullock²

¹Experimental Pathology Program, University of Virginia , Charlottesville, VA , USA.

Frontiers in Immunology

|February 14, 2014

Summary

This summary is machine-generated.

Dendritic cells (DCs) regulate immune responses. Tumor-associated DCs often show impaired metabolism, reducing their ability to fight cancer. Targeting DC metabolism could enhance cancer immunotherapy.

Keywords:

activation cancer immunotherapy dendritic cell glycolysis lipid metabolism metabolism oxidative phosphorylation tumor-associated dendritic cell

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Related Experiment Videos

Last Updated: May 3, 2026

Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro

Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro

Published on: March 7, 2022

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Area of Science:

Immunology
Cancer Biology
Metabolic Regulation

Background:

Dendritic cells (DCs) are key immune regulators, controlling adaptive immunity activation and tolerance.
Tumor-associated DCs (TADC) in the tumor microenvironment (TME) are often inactivated, hindering anti-tumor responses.
Emerging evidence links DC metabolic alterations to their reduced immunostimulatory function.

Purpose of the Study:

To review the role of DC metabolism, specifically glycolysis and fatty acid metabolism, in DC activation and function.
To discuss how the TME influences TADC metabolism and contributes to their dysfunction.
To highlight the need for in vivo metabolic assessment and integration of metabolic strategies in DC-based cancer therapies.

Main Methods:

Review of existing literature on dendritic cell activation, metabolism, and tumor microenvironment interactions.
Analysis of metabolic pathways including glycolysis and fatty acid metabolism in DCs.
Discussion of experimental approaches for in vivo metabolic assessment.

Main Results:

DC activation involves coordinated metabolic shifts, including changes in glycolysis and fatty acid metabolism.
The TME actively promotes metabolic dysregulation in TADCs, impairing their immunostimulatory capacity.
Dysfunctional TADC metabolism is directly associated with reduced anti-tumor immune responses.

Conclusions:

Metabolic pathways are crucial for DC function and activation.
Targeting TADC metabolism presents a promising strategy for improving cancer immunotherapy and vaccine development.
Novel in vivo methods are needed to fully understand and manipulate DC metabolic choices for therapeutic benefit.